A new Medicare option for weight loss drugs is coming: Here's what to know

Jackie Fortiér / npr - Millions of people with Medicare will soon be eligible to get discounted GLP-1 drugs for weight loss. Here's how it will work.

AI Summary: Medicare is introducing a new option to expand access to weight‑loss medications for older Americans, outlining eligibility, coverage mechanics and likely impacts on beneficiaries and budgets. The guidance aims to help clinicians and patients navigate coverage decisions and prepares stakeholders for shifts in prescribing patterns and costs as demand for GLP‑1 class drugs remains high.


Competition, dosing and long-term weight strategies

Daily pill to help keep weight off after stopping obesity jabs

1 month / bbc

Lilly points to low-dose Zepbound and Foundayo as weight loss maintenance options

1 month / endpoints / Elizabeth Cairns

Bariatric surgery leads to 20-percentage point greater weight loss than GLP-1s: Analysis

1 month / beckershospitalreview / Elizabeth Casolo

Rezdiffra is exceeding Wall Street's expectations as the MASH market takes shape

1 month / endpoints / Nicole DeFeudis


Efficacy and safety of GLP‑1s in older adults

GLP-1s linked to higher breast cancer survival: 3 notes

1 month / beckershospitalreview / Elizabeth Gregerson

Pooled analysis reveals semaglutide shows good efficacy in older adults aged over 65 years

2 months / medicalxpress

New post-hoc analysis examined daily oral orforglipron in adults over 65 with obesity, with or without diabetes

2 months / medicalxpress


Medicare expansion and coverage landscape

About 67% of Employers Cover GLP-1s for Weight Management; That Could Decline in 2027

1 month / medcitynews / Marissa Plescia

A new Medicare option for weight loss drugs is coming: Here's what to know

2 months / npr / Jackie Fortiér

A New Medicare Option for Weight Loss Drugs: What Older Americans Should Know

2 months / kffhealthnews / Jackie Fortiér


All Other Stories

Weight-loss drugs tied to lower death, recurrence risk after breast cancer

7 wks / medicalxpress

Muscle mass is preserved after obesity drug treatment, study suggests

7 wks / medicalxpress

Analysis shows how using obesity drugs for weight loss is associated with a clinically relevant drop in blood pressure

1 month / medicalxpress

New obesity guidance urges dietitian-led care as GLP-1 drugs reshape treatment

1 month / medicalxpress

Trial shows rapid weight loss is much more effective than gradual weight loss, challenging prevailing beliefs

1 month / medicalxpress

Medicare’s GLP-1 program is 6 weeks out: What it means for health systems

1 month / beckershospitalreview / Ella Jeffries

Some Medicare Patients Can Now Get Free CBD

1 month / nytimes / Jan Hoffman

Wegovy initiation may cut migraine drug use 8% in women after one year

1 month / medicalxpress

Study links use of new obesity drugs to reduction of asthma exacerbations and inhaler use

1 month / medicalxpress

Medicare Coverage for GLP-1 Weight Loss Drugs: Cost, Eligibility and What to Know

1 month / nytimes / Mark Miller

Semaglutide cuts BMI by 19% in treatment-resistant young adults with severe obesity, finds trial

1 month / medicalxpress

Study shows that people who gain the most weight are at more than double the risk of certain cancers

1 month / medicalxpress

Higher BMI is associated with more financial problems, loneliness and stress

1 month / medicalxpress

Review shows obesity drugs, obesity surgery lead to a higher proportion of fat-free mass loss than diet and exercise

1 month / medicalxpress

Most weight loss achieved using injectable obesity drugs can be maintained by switching to orforglipron, study shows

1 month / medicalxpress

Continuing tirzepatide at full dose helps preserve weight loss over 112 weeks

1 month / medicalxpress

How do weight-loss drugs like Mounjaro and Wegovy work?

1 month / bbc

GLP-1 Receptor Agonists Show a Striking Signal in Breast Cancer Outcomes, but Big Questions Remain

1 month / oncodaily

Study shows use of obesity drugs alongside behavioral intervention is associated with reduced 'food noise'

1 month / medicalxpress

Framework for the pharmacological treatment of obesity and its complications from the European Association for the Study of Obesity (EASO): 2026 update

1 month / nature / Andreea Ciudin

Pasteurized Akkermansia muciniphila MucT for weight loss maintenance in people with overweight and obesity: a controlled randomized trial

1 month / nature / Sarah Mount

Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial

1 month / nature / Louis J. Aronne

After weight loss, the body keeps pulling back—and this study shows how hard

1 month / medicalxpress

Could the 'Ozempic Era' shift blame for obesity from individuals to the food industry?

2 months / medicalxpress

Back to Top / Sat, May 9, 2026, 10:21 am / permalink 23513 / 34 stories in 2 months /




Related Stories

Medicare GLP‑1 expansion spurs retailer programs and policy debate / 13 days

Optum Rx/Caremark and FTC edge toward settlement in insulin case / 4 months

CMS delays Medicare GLP-1 pilot amid insurer skepticism / 2 months

Eli Lilly launches Employer Connect to broaden GLP‑1 coverage / 4 months

Hospitals push regulators to block expanded 340B claims reporting requirements / 4 months

Trump Administration Secures Lower Obesity Drug Prices / 8 months

CVS sues Tennessee over PBM‑pharmacy separation law / 6 wks

StackHealth RSS

You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Pfizer, Corporate Takeover, Product Recall, Supplements and look for the RSS link.




↑

NorthFeed Inc. Terms and Conditions / Privacy Policy

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.